MedTrace Logo

Simplified Treatment of Anti-retrovirus in China (C-STAR)

NCT03603977 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 600

Last updated 2022-09-14

No results posted yet for this study

Summary

To observe the efficacy and safety of simplified therapy regimen for treating with HIV-1 infected patients in Chinese real word.

Conditions

Interventions

DRUG

Lpv/r+3TC

It is a simplified therapy regimen study of lopinavir and ritonavir combined with lamivudine for HIV-1 infected patients in the real world of China.

Sponsors & Collaborators

  • Guiyang Public Health Clinical Center

    collaborator UNKNOWN

  • The Third People's Hospital of Kunming

    collaborator UNKNOWN

  • The Second People's Hospital of Nanjing

    collaborator UNKNOWN

  • Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

    collaborator OTHER

  • The Third People's Hospital of Guilin

    collaborator UNKNOWN

  • Guangxi Longtan hospital

    collaborator UNKNOWN

  • The Fourth People's Hospital of Nanning

    collaborator OTHER

  • LiuZhou People's Hospital

    collaborator OTHER

  • Tianjin Second People's Hospital

    collaborator OTHER

  • The Sixth People's Hospital of Shenyang

    collaborator OTHER

  • The Sixth People's Hospital of Henan

    collaborator UNKNOWN

  • The Sixth People's Hospital of Xinjiang

    collaborator UNKNOWN

  • The Eighth People's Hospital of Xi'an

    collaborator UNKNOWN

  • Guangzhou 8th People's Hospital

    lead OTHER

Principal Investigators

  • Weiping Cai, Bachelor · Guangzhou 8th People's Hospital

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-11-01
Primary Completion
2025-12-31
Completion
2030-10-31

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03603977 on ClinicalTrials.gov